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Abstract
Objective: Triptolide is the major active component of Tripterygium wilfordii Hook. f., which has
been used as an anti-inflammatory agent in traditional Chinese medicine for centuries. The
mechanisms of the anti-inflammatory effects of triptolide in renal diseases are not well understood.
Recent studies have shown that overexpression of monocyte chemoattractant protein-1 in renal
tubular epithelial cells is associated with the inflammatory injuries of renal tubulointerstitium. In
this study, we investigated the effect of triptolide on the overexpression of monocyte chemoattractant
protein-1 in renal tubular epithelial cells in vitro.
Methods: Human proximal tubular epithelial cells were treated with gamma interferon (200 µg/L)
and tumor necrosis factor-alpha (20 µg/L) or combined with different concentrates of triptolide (0.4,
2, 10 µg/L) for 12 hours (for monocyte chemoattractant protein-1 mRNA measuring) or 24 hours (for
monocyte chemoattractant protein-1 protein measuring). The expression of monocyte chemoattractant
protein-1 mRNA was detected by using reverse transcriptase-polymerase chain reaction. The
expression of monocyte chemoattractant protein-1 protein in the cells was measured by using flow
cytometry. Monocyte chemoattractant protein-1 levels in the supernatant were measured by using
the enzyme-linked immunosorbent assay method.
Results: After treatment with interferon-γ and tumor necrosis factor-α, monocyte chemoattractant
protein-1 mRNA and protein levels in human proximal tubular epithelial cells and monocyte
chemoattractant protein-1 concentrations in the supernatant were significantly increased. Triptolide
(10 µg/L) can significantly inhibit the overexpression of monocyte chemoattractant protein-1 mRNA
and protein in human proximal tubular epithelial cells. The increase of monocyte chemoattractant
protein-1 protein in the supernatant was also markedly inhibited by triptolide (2, 10 µg/L).
Conclusions: The results of this study suggest that the inhibition of monocyte chemoattractant
protein-1 overexpression in tubular epithelial cells may contribute to the anti-inflammatory effects
of triptolide in renal diseases.
Key words: Epithelial cells/immunology, Enzyme-linked immunosorbent assay, Kidney tubules/pathology,
Nuclear factor-kappaB (NF-κB), Tripolide
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Overexpression of monocyte chemoattractant protein-1 in human proximal tubular epithelial cells
INTRODUCTION
Tubulointerstitial inflammation is a common feature of
many kinds of renal diseases, and is especially severe in
tubulointerstitial nephritis, type IV lupus nephritis, renal
vasculitis, and acute cellular rejection after renal
transplantation. Several studies have demonstrated that
impairment of the glomerular filtration rate correlates
directly with the severity of tubulointerstitial inflam-
mation and fibrosis (1,2). The migration of immune cells,
including lymphocytes, monocytes, and neutrophils into
the renal tubulointerstitium is the hallmark of tubulo-
interstitial inflammation (3). Monocyte chemoattractant
protein-1 (MCP-1) is a powerful chemoattractant factor
for monocytes and lymphocytes (4,5). The normal kidney
expresses small amounts of MCP-1, but MCP-1
expression is significantly increased in several renal
diseases and animal models, including ischemia (6),
glomerulonephritis (7), diabetic nephropathy (8), lupus
nephritis (9), and partial nephrectomy (10). Renal tubular
epithelial cells have proved to be an important source of
MCP-1 in tubulointerstitium (11-14). Data from humans
(15,16) and experimental animals (11,13) suggest
strongly that overexpression of MCP-1 in tubular
epithelial cells is responsible for tubulointerstitial
inflammation and damage of the infiltrated structure.
Tesch et al (17) reported that leukocytic infiltration in
renal tubulointerstitium in MRL-Fas (lpr) mice is MCP-
1-dependent. Okada et al (18) reported that the inhibi-
tion of MCP-1 expression in tubular epithelium by
intravenously administered antisense oligodeoxy-
nucleotide attenuates tubulointerstitial lesions in
Goodpasture syndrome.
Triptolide is the major active component of Tripterygium
wilfordii Hook. f. (TWHf), which has been used as an
anti-inflammatory agent in traditional Chinese medicine
for centuries (19,20). Although triptolide has been proven
to have unique effects for the therapy of inflammatory
renal diseases (eg, immunoglobulin A nephropathy, lupus
nephritis, tubulointerstitial nephritis, and acute rejection
after renal transplantation) (21,22), the mechanisms are
still not well understood. To further understand the
mechanism of the immunosuppressive activity of
triptolide, we investigated the effect of triptolide on the
overexpression of MCP-1 in human proximal tubular
epithelial cells.
METHODS
Reagents
Triptolide (purity >99%) was obtained from the Institute
of Dermatology, Chinese Academy of Medical Sciences
(Nanjing, China) (23). Human gamma interferon (IFN-
γ) was purchased from PharMingen (San Diego, CA,
US). Human recombinant tumor necrosis factor-alpha
(TNF-α) was purchased from Promega (Madison, WI,
US). Monoclonal mouse anti-human MCP-1 antibody
and fluorescein isothiocyanate labeled rabbit anti-mouse
immunoglobulins were purchased from DAKO
(Glostrup, Denmark). The enzyme-linked immuno-
sorbent assay (ELISA) kit used for the quantitative
measurement of human MCP-1 was purchased from
Endogen (Woburn, MA, US).
Cell culture
The human renal proximal tubular epithelial cell line
(HKC) was established in the 1990s by Professor LC
Racusen from the Johns Hopkins University School of
Medicine (24), and has been widely used in recent years
(25). The HKC cells used in this experiment were a gift
from Professor FL Zheng (Peking Union Medical
College) (26), and were maintained in RPMI 1640
medium (GIBCO BRL, Grand Island, NY, US) containing
10% heat-inactivated fetal bovine serum in a 25-cm2
tissue culture flask. Cells in passages 10 to 15 were used
in this study. Cells at 80% to 90% confluence were
cultured in serum-free medium for 24 hours before being
treated with IFN-γ (200 µg/L), TNF-α (20 µg/L), and
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various concentrations of triptolide (0.4, 2, 10 µg/L) for
another 24 hours. Cells without any treatment or those
only treated with IFN-γ and TNF-α served as controls.
Reverse transcriptase-polymerase chain
reaction
Human proximal tubular epithelial cells at 80% to 90%
confluence were cultured in serum-free medium for 24
hours, then treated with RPMI 1640/10% containing IFN-
γ (200 µg/L), TNF-α (20 µg/L), and various concentrations
of triptolide (2, 10 µg/L) for 12 hours. Total cellular RNA
was isolated using Trizol reagent (Sangon, Shanghai,
China) in accordance with the manufacturer’s instructions.
After assessing the purity of the final products by optical
density ratios at 260:280 nm, RNA samples were then
reverse transcribed into cDNA by using a reverse-
transcription kit (Promega). The human MCP-1 primers
were 5'-AAC TGA AGC TCG CAC TCT CG-3' (sense)
and 5'-TCA GCA CAG ATC TCC TTG GC-3' (antisense),
and yielded a 258 base pair product. A pair of porcine β-
actin primers was used at the same time as a control: 5'-
CTA CAA TGA GCT GCG TGT GG-3' (sense) and 5'-
TAG CTC TTC TTC AGG GAG GA-3' (antisense), and
yielded a 450 base pair product. After amplification,
polymerase chain reaction products were electrophoresed
through a 2% agarose gel with ethidium bromide 0.5 mg/
L to visualize the DNA bands. The results were obtained
and analyzed by using a BF-300 image system provided
by Sixing Biotech (Shanghai, China).
Flow cytometry
For flow cytometry analysis, HKC cells (1 x 106) were
harvested by using Versene solution (0.02% ethyl-
enediaminetetraacetic acid), washed twice in 1 mL of
phosphate buffered saline (0.01 mol/L, pH 7.4), fixed in
0.1% paraformaldehyde for 15 minutes, and then washed
and incubated in 200 µL of phosphate buffered saline
containing 0.5% bovine serum albumin and 0.02% Na3N
for 40 minutes at 4oC with mouse anti-human MCP-1
antibody. Then the cells were washed and incubated with
fluorescein isothiocyanate-conjugated rabbit anti-mouse
immunoglobulin G in the dark at 4oC for 30 minutes.
The antibodies were diluted to recommended con-
centrations according to the manufacturers’ instructions.
Background fluorescence was adjusted with cells labeled
with mouse control antibodies as the first antibody.
Analyses were performed on a Coulter flow cytometer
(Miami, FL, US).
Enzyme-linked immunosorbent assay
Monocyte chemoattractant protein-1 levels in the
supernatant were measured by using an ELISA kit in
accordance with the manufacturer’s instructions. In brief,
culture supernatants were collected and centrifuged (3000
rpm, 5 minutes) before use. Then the samples and the
biotinylated antibody reagent were incubated in
precoated wells at room temperature for 2 hours. The
plate was washed three times, then streptavidin-
horseradish peroxidase solution was added and incubated
at room temperature for 30 minutes. The plate was
washed three times, and premixed tetramethylbenzidine
substrate solution was added and incubated at room
temperature for another 30 minutes. The reaction was
terminated with provided stop solution. The plate was
read at 450 nm in an ELISA reader. Standards were 1/2
log dilutions of recombinant human MCP-1, from 0 to
2000 pg per well. Total protein levels in the supernatant
were also measured by using the Bradford method to
evaluate the secretion activity of HKC.
Statistical analysis
Data were expressed as mean ± standard deviation. One-
way analysis of variance and the F test were used to
evaluate statistical significance. A difference was
considered statistically significant if p<0.05.
RESULTS
Interferon-γ and tumor necrosis factor-α
-induced monocyte chemoattractant
protein-1 expression in human proximal
tubular epithelial cells
Normal HKC cells express small amounts of MCP-1.
After being treated with IFN-γ (200 µg/L) and TNF-α
(20 µg/L) together for 24 hours, MCP-1 levels in HKC
cells significantly increased (Fig. 1). Although the total
protein in the supernatants was not changed markedly,
the MCP-1 levels in the supernatants resulted in a seven-
fold increase after the IFN-γ and TNF-α treatment (1120.
9 ± 71.9 vs 141.9 ± 17.3 µg/L, p<0.01). When treated
with IFN-γ and TNF-α for 12 hours, The MCP-1 mRNA
Figure 1. IFN-γ- and TNF-α-induced up-regulation of MCP-1
synthesis in human proximal tubular cells. (A) Negative control,
(B) unstimulated cells, and (C) cells stimulated with IFN-γ (200 µg/
L) and TNF-α (20 µg/L) for 24 hours.
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levels in HKC cells also significantly increased (Fig. 2).
Triptolide inhibits the overexpression of
monocyte chemoattractant protein-1
Triptolide inhibits the increase of MCP-1 protein induced
by TNF-α and IFN-γ in HKC cells. The mean flu-
orescence intensity in the triptolide group (10 µg/L) was
significantly lower than that in the TNF-α and IFN-γ
groups (Table 1). The increases of MCP-1 proteins in
the supernatants and MCP-1 mRNAs in HKC cells were
also markedly inhibited by triptolide (Figs. 2 and 3).
DISCUSSION
The studies presented herein describe triptolide-mediated
down-regulation of induced MCP-1 expression in human
renal tubular epithelial cells.
Tripterygium wilfordii Hook. f. has been used in
traditional Chinese medicine for centuries. The extract
of the herb has been prescribed for the treatment of a
variety of autoimmune diseases, such as rheumatoid
arthritis (27), nephritis (22), and systemic lupus
erythematosus (28,29), and is being tried as an immuno-
suppressant in organ and tissue transplantations (21,30).
Many compounds have been identified from the extract
of TWHf, including diterpenoids (such as triptolide and
tripdiolide), alkaloids, glycosides, β-sitosterol, and
triptoquinones (27). Previous studies have shown that
triptolide, also named PG490, is the most efficient
constituent of TWHf (31) with potent immuno-
suppressive and anti-inflammatory abilities. Although
triptolide is often used to replace corticoid in patients
who cannot tolerate corticoid therapy, it may have
different effects in the therapy of inflammatory renal
diseases and allograft rejections. Li et al (21) found that
triptolide is useful in some patients who have im-
munoglobulin A nephropathy when corticoid is not
effective. Chan et al (32) reported that triptolide is more
effective in preventing T-cell proliferation and IFN-γ
production than is FK506. Some other ingredients of
TWHf, such as tripdiolide and tripcholorolide, have also
been proven by some experimental systems to have
immunosuppressive effects, but their effects do not seem
to be as strong as those of triptolide (33,34).
Much work has been performed to investigate the
mechanisms of the potent anti-inflammatory effects of
triptolide. Studies have shown that triptolide inhibits
mitogen-induced lymphocyte proliferation, the mixed
lymphocyte reaction, the generation of cytotoxic T cells,
and induces apoptotic death of T lymphocytes (23,35,
36). Qiu et al (37) reported that triptolide inhibits T-cell
interleukin-2 expression at the level of the purine-box/
nuclear factor of activated T-cells and nuclear factor-
kappaB (NF-κB) transcriptional activation. In contrast,
Yang et al (38) reported that triptolide suppresses T-
lymphocyte proliferation by inhibiting interleukin-2
receptor expression rather than interleukin-2. Previously,
we found that triptolide can markedly increase adenosine
3',5'-cyclic monophosphate/protein kinase A activity in
T lymphocytes (39). Our recent work indicates that
Table 1. The effect of triptolide on the expression of MCP-1 in
HKC cells.*
Group No. MCP-1
Control 4 4.70 ± 0.78
IFN-γ (200 µg/L) + TNF-α (20 µg/L) 4 7.92 ± 1.69†
IFN-γ + TNF-α + triptolide (0.4 µg/L) 4 7.70 ± 1.96
IFN-γ + TNF-α + triptolide (2 µg/L) 4 6.62 ± 1.20
IFN-γ + TNF-α + triptolide (10 µg/L) 4 4.76 ± 1.05‡
*Data show the mean fluorescence intensities detected by flow
  cytometry.
†p<0.01 vs the control group.
‡p<0.01 vs the “IFN-γ + TNF-α” group. Figure 2. Triptolide inhibits MCP-1 mRNA overexpression in human
proximal tubular cells induced by IFN-γ and TNF-α (n = 3). Lane 1,
normal control; lane 2, cells treated with TNF-α (20 µg/L) and IFN-
γ (200 µg/L) for 12 hours; lane 3, cells treated with triptolide (2 µg/
L), TNF-α, and IFN-γ for 12 hours; and lane 4, cells treated with
triptolide (10 µg/L), TNF-γ, and IFN-γ for 12 hours. *p<0.01 vs
control; †p<0.01 vs IFN-γ and TNF-α groups.
Figure 3. Monocyte chemoattractant protein-1 levels in the
supernatants of different groups (n = 4). *p=0.01 vs control. †p<0.01
vs IFN-γ and TNF-α groups. Trip = triptolide.
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triptolide is a potent inhibitor of NF-κB activation in T
lymphocytes and this effect is partly attributed to the
up-regulation of IκBα mRNA expression (40). However,
in previous studies, we focused on triptolide’s effects on
lymphocytes; the effects of triptolide on the immune
abilities of renal tubular epithelial cells are still not
understood.
CONCLUSIONS
In this study, we focused on the impact of triptolide on
MCP-1 expression of renal tubular epithelial cells and
demonstrated that triptolide can markedly inhibit the
induced up-regulation of MCP-1 molecules in renal
tubular epithelial cells. These findings suggest that the
inhibition of MCP-1 overexpression in tubular epithelial
cells may also contribute to the anti-inflammatory effects
of triptolide. Previous studies have shown that the MCP-
1 gene is transcriptionally regulated by NF-κB (41,42),
and recent work has shown that triptolide is a potent
inhibitor of NF-κB activation in T lymphocytes (40),
human bronchial epithelial cells (37), and tumor cells
(43). We speculate that the inhibitory effect of triptolide
on MCP-1 expression in tubular epithelial cells may be
attributed to its effect on the activation of NF-κB. This
hypothesis and the in vivo effect of triptolide on the MCP-
1 expression in tubular epithelial cells requires further
investigation.
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